Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIUMVI vs ADUHELM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Treatment of Alzheimer's disease (FDA approved for patients with mild cognitive impairment or mild dementia stage of disease)
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
Terminal elimination half-life is approximately 26 days (range 19–34 days), supporting monthly intravenous dosing. The long half-life reflects the slow clearance of Ig G1 monoclonal antibodies.
Ublituximab is a monoclonal antibody catabolized into small peptides and amino acids via general protein degradation pathways; no specific metabolic enzymes are involved.
Aducanumab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous Ig G. No specific cytochrome P450 enzymes are involved.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
ADUHELM is eliminated primarily via catabolism into small peptides and amino acids. No renal or biliary excretion of intact monoclonal antibody is expected. Clearance is via the reticuloendothelial system; approximately 97% is metabolized, with <3% excreted as intact antibody in urine.
Not extensively bound to plasma proteins (expected low binding for monoclonal antibodies); specific % not reported.
Approximately 99% bound, primarily to endogenous Ig G (via Fc Rn binding) and other plasma proteins; specific binding proteins include Fc Rn.
Approximately 3.5 L (not weight-based; ~0.05 L/kg for a 70 kg patient). Small Vd consistent with limited extravascular distribution of monoclonal antibodies.
Volume of distribution is approximately 6.8 L (central compartment), equivalent to plasma volume; does not distribute extensively into tissues due to large molecular size. In L/kg: ~0.1 L/kg for a 70 kg patient.
100% (intravenous administration only; not administered via other routes).
Intravenous administration results in 100% bioavailability. No subcutaneous or oral formulation is available; thus no bioavailability for other routes.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and effectiveness in pediatric patients (age <18 years) have not been established. No recommended dosing.
Safety and efficacy have not been established in pediatric patients. No recommended dosing available.
No specific dose adjustment is recommended. Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
None
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Aducanumab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be serious and life-threatening. ARIA generally occurs within the first 8 doses. Monitoring with MRI is required prior to and during treatment.
Infusion reactions (may require premedication and monitoring),Increased risk of infections (including serious and life-threatening infections),Progressive multifocal leukoencephalopathy (PML) in patients treated with anti-CD20 therapies,Hepatitis B reactivation (perform HBV screening before initiation),Immunoglobulin levels reduction requiring monitoring,Increased risk of malignancies (breast cancer observed in clinical trials)
Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H,Hypersensitivity reactions including angioedema and urticaria,Risk of seizures (reported in clinical trials),Concomitant use of antithrombotic medications may increase risk of intracranial hemorrhage
Active hepatitis B infection,Severe, active infections (until resolved)
Known hypersensitivity to aducanumab or any excipients of ADUHELM
No known food interactions. Grapefruit and other CYP450 modulators are not expected to affect ublituximab as it is a monoclonal antibody cleared via catabolism.
No specific food interactions reported. Patients should maintain a balanced diet as part of overall health management. Avoid grapefruit juice if taking other medications metabolized by CYP3A4, though aducanumab is not metabolized by CYP enzymes.
BRIUMVI (ublituximab) is a monoclonal antibody, and Ig G antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimester. Based on its mechanism of action (CD20-mediated B-cell depletion), there is a potential risk of transient peripheral B-cell depletion in the fetus. Animal studies have not been conducted with ublituximab; however, other anti-CD20 antibodies have shown no teratogenicity but can cause neonatal B-cell depletion. The drug should be avoided during pregnancy unless the benefit justifies the potential risk.
No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal reproductive studies available. Use only if benefit outweighs potential risk.
It is unknown whether ublituximab is excreted in human milk. Monoclonal antibodies are generally present in breast milk in low amounts, but absorption by the infant is limited due to gastrointestinal degradation. Since ublituximab can cause B-cell depletion, a risk to the breastfed infant cannot be excluded. The M/P ratio is not known.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Aducanumab is a large Ig G molecule; likely excreted into milk in low amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data. However, pregnancy can alter clearance and volume of distribution for monoclonal antibodies, potentially affecting exposure. Current guidelines do not specify dose modifications for ublituximab in pregnancy; clinical judgment is advised.
No pharmacokinetic data during pregnancy. Dose adjustments not established. Administer same dose as non-pregnant adults (10 mg/kg IV monthly after titration) unless significant infusion reactions occur.
Premedicate with corticosteroids, antihistamines, and acetaminophen to reduce infusion reactions. Monitor for hypersensitivity reactions, especially during first infusion. Screen for hepatitis B and tuberculosis before initiation. Avoid live vaccines during treatment. Consider JCV antibody status due to risk of progressive multifocal leukoencephalopathy (PML) with anti-CD20 therapies.
ADUHELM (aducanumab-avwa) is a monoclonal antibody targeting aggregated forms of beta-amyloid. It is indicated for Alzheimer disease. Confirmation of amyloid beta pathology via PET or CSF is required before initiation. Titration over 6-8 months is mandatory to reduce risk of amyloid-related imaging abnormalities (ARIA). Monitor for ARIA with MRI prior to the 7th and 12th infusions; suspend dosing if ARIA is detected. Adverse effects include ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition). Coadministration with anticoagulants may increase risk of ARIA-H. Assess for hypersensitivity reactions. No specific reversal agent is available.
You must take premedications before each infusion to lower the risk of allergic reactions.,Report any symptoms like fever, chills, rash, or difficulty breathing during or after infusion.,Inform your doctor if you have a history of hepatitis B, tuberculosis, or any infections.,Do not receive live vaccines while on this medication and for a period after stopping.,This drug may increase your risk of infections; contact your doctor if you develop signs of infection.,You will need regular blood tests to monitor for side effects.
This drug is for patients with mild cognitive impairment or mild Alzheimer disease confirmed by amyloid PET or CSF testing.,Treatment requires intravenous infusion every 4 weeks, with dose titration over at least 6 months.,MRI scans are needed before and during treatment to monitor for brain swelling or small bleeds (ARIA).,Tell your doctor immediately if you experience headache, confusion, dizziness, vision changes, nausea, or seizures.,Avoid blood thinners like warfarin, apixaban, or rivaroxaban unless prescribed; they may increase bleeding risk.,Do not drive or operate heavy machinery if you experience dizziness or visual disturbances.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Store vials in refrigerator and protect from light; do not freeze or shake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIUMVI vs ADUHELM, answered by our medical review team.
BRIUMVI is a Monoclonal Antibody that works by BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.. ADUHELM is a Anti-Amyloid Beta Monoclonal Antibody that works by Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIUMVI and ADUHELM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIUMVI is: BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.. The standard adult dose of ADUHELM is: 10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIUMVI and ADUHELM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIUMVI is classified as Category C. BRIUMVI (ublituximab) is a monoclonal antibody, and IgG antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimes. ADUHELM is classified as Category C. No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal repr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.